LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $76.49 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-02-27
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $76.49M.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $46.37M.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $17.81M.
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $12.35M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months as first filed |
|---|---|---|
| 2025-12-31 | $76.49M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $46.37M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $17.81M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $12.35M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $53.95M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $26.23M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $8.02M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $46.04M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $365.72M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $137.95M 10-K · filed 2021-02-24 | $137.95M 10-Q · filed 2020-05-08 |